S-equol ERβ Agonist Modulation for TNBC and Melanoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly for triple-negative breast cancer (TNBC) and melanoma, face limitations in efficacy and safety, with immunotherapies showing modest results and chemotherapy inducing unnecessary toxicity, highlighting the need for more effective and safer treatments that target estrogen receptor beta (ERβ) for enhanced antitumor activity.
Innovation Solution
The use of S-equol, an ERβ agonist, in combination with immunotherapy, such as anti-PD-1 antibodies, to activate T-cell receptor signaling and boost immunotherapy, thereby stimulating ERβ phosphotyrosine switch and enhancing antitumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat triple-negative breast cancer, then tumor growth is suppressed, but toxicity increases without substantial clinical benefits
Solution Approach 1:
The patent changes the therapeutic parameter from conventional chemotherapy to S-equol, an ERβ-selective agonist. This parameter change achieves tumor growth suppression through a different mechanism (ERβ activation in immune cells) that avoids the toxicity associated with chemotherapy, thereby resolving the contradiction between efficacy and harmful effects
Solution Approach 2:
The patent introduces ERβ activation as an intermediary mechanism between treatment administration and tumor suppression. S-equol acts as a mediator that activates ERβ in immune cells (particularly CD8+ T cells and NK cells), which then mediates the antitumor effect through immune response enhancement, bypassing the direct toxic effects of chemotherapy
2Reliability
If immunotherapy is used to treat cancer, then immune response is enhanced, but efficacy remains modest
Solution Approach 1:
The patent changes the immunotherapy parameter by introducing ERβ activation as a novel mechanism. Instead of using conventional immune checkpoint inhibitors alone, the patent activates ERβ in immune cells through S-equol, which enhances T-cell receptor signaling and immune cell function, thereby improving clinical efficacy while maintaining immune response enhancement
Solution Approach 2:
The patent applies preliminary action by activating ERβ in immune cells before or during cancer treatment. This preliminary activation of ERβ in CD8+ T cells and NK cells primes the immune system to respond more effectively to tumor antigens, enhancing the overall efficacy of the immunotherapy approach
Data Source
AI summary
The present invention provides methods and compositions for modulating molecular markers, and hence treating or preventing breast cancer (e.g., triple-negative breast cancer) and melanoma with a pharmaceutically effective amount of S-equol or a pharmaceutical composition comprising S-equol. The S-equol may be administered alone or in combination with one or more cytotoxic or immunotherapeutic compound or molecule.